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Objectives. The purpose of this retrospective evaluation of advanced-stage ovarian cancer patients was to compare outcome with
published ﬁndings from other centers and to discuss future options for the management of advanced ovarian carcinoma patients.
Methods. A retrospective series of 340 patients with a mean age of 58 years (range: 17–88) treated for FIGO stage III and IV ovarian
cancer between January 1985 and January 2005 was reviewed. All patients had primary cytoreductive surgery, without extensive
bowel, peritoneal, or systematic lymph node resection, thereby allowing initiation of chemotherapy without delay. Chemotherapy
consisted of cisplatin-based chemotherapy in combination with alkylating agents before 2000, whereas carboplatin and paclitaxel
regimes were generally used after 1999-2000. Overall survival and disease-free survival were analyzed by the Kaplan-Meier method
and the log-rank test. Results. With a mean followup of 101 months (range: 5 to 203), 280 events (recurrence or death) were
observed and 245 patients (72%) had died. The mortality and morbidity related to surgery were low. The main prognostic factor
for overall survival was postoperative residual disease (P<. 0002), while the main prognostic factor for disease-free survival was
histological tumor type (P<. 0007). Multivariate analysis identiﬁed three signiﬁcant risk factors: optimal surgery (RR = 2.2f o r
suboptimal surgery), menopausal status (RR = 1.47 for postmenopausal women), and presence of a taxane in the chemotherapy
combination (RR = 0.72). Conclusion. These results conﬁrm that optimal surgery deﬁned by an appropriate and comprehensive
eﬀort at upfront cytoreduction limits morbidity related to the surgical procedure and allows initiation of chemotherapy without
any negative impact on survival. The impact of neoadjuvant chemotherapy to improve resectability while lowering the morbidity
of the surgical procedure is discussed.
1.Introduction
Epithelial ovarian cancer is diagnosed in 4,500 women per
year in France and represents 3.8% of all female cancers
worldwide [1] .I n2o u to f3c a s e s[ 2], it is diagnosed
at an advanced stage, (stage III or IV) according to
the International Federation of Gynecology and Obstetrics
(FIGO) classiﬁcation. It is commonly agreed that treatment
should consist of primary cytoreductive surgery followed by
platinum-based chemotherapy. The outcome of epithelial2 International Journal of Surgical Oncology
ovarian cancer appears highly dependent on the results
achieved by primary surgery, as shown in the meta-analysis
by Bristow et al. in 2002 [3]. The smaller the residual disease,
the better is the prognosis. In order to achieve this minimal
residual disease, surgeons have attempted more aggressive
procedureswithextensiveresectionofbowelandperitoneum
in addition to the total abdominal hysterectomy, bilat-
eralsalpingo-oophorectomy(TAH-BSO),andomentectomy.
Systematic pelvic and paraaortic lymph node dissections
also still remain controversial. However, while the quality of
surgical resection is dependent on the extent of disease and
the multiplicity of peritoneal deposits, additional parame-
ters,pertainingtotumoraggressivebehaviorandparticularly
vascularity and adhesion, may defy the best surgical skills.
At Institut Curie, successive surgical teams have refrained
fromoverlyaggressivesurgery,sourceofincreasedmorbidity
or even intraoperative, or postoperative death [4]. Our
attitude over time has been that of an “appropriate and
comprehensive” eﬀort at upfront cytoreduction allowing an
uncomplicated postoperative course and rapid initiation of
chemotherapy in most cases.
The disease-free and survival results of this surgical
attitude followed by chemotherapy were analyzed in this
retrospectivestudyrelatingtothis20-yearexperience.Future
management options, particularly chemotherapy tailored to
histologic or molecular/genetic subtype, number of courses
of neoadjuvant chemotherapy as well as preventive surgery
in high-risk patients, and the assessment of biological factors
will be discussed.
2. Patientsand Methods
Between 1985 and 2005, 340 out of 420 patients treated for
ovarian cancer at the Institut Curie with FIGO stage III or
IV disease were analyzed in this retrospective study. All 340
patients had undergone primary surgery designed to achieve
resection as complete as possible, that is, residual disease
measuring ≤1 cm. Following initial peritoneal cytology, the
operation consisted of TAH-BSO, omentectomy, possibly
associated with bowel resections (appendicectomy and/or
bowel resection) and multiple peritoneal biopsies. Pelvic
and paraaortic lymph node dissection was performed in the
presence of palpable nodes.
All histopathology slides were reviewed to assess tumor
grade according to current criteria and, whenever necessary,
tumors were reclassiﬁed according to their histologic type
(particularly to avoid confusion between mucinous tumors
and metastasis from bowel tumors) [5, 6].
Perioperative complications or death were deﬁned as
adverse events, when they occurred within 30 days of surgery
according to the Memorial Sloan-Kettering Cancer surgical
events grading system [7].
Following surgery, patients started ﬁrst-line chemother-
apy within a median interval of 27 days. Before 2000,
chemotherapy consisted of two schedules given sequentially
every10days(OvaireA)for9injectionsfollowedby3weekly
(Ovaire B) courses administered for 3 courses. Ovaire A
consisted of Isofosfamide 1.4g/m2 on days 1, 2, and 3 as
well as CDDP 1mg/kg and 5FU 600mg/m2 day, on days 1,
10, and 20. Ovaire B consisted of Isofosfamide 1.4g/m2 on
days 1 to 3, CDDP 75mg/m2 on day 1, and 5FU 600mg/m2
on day 1. From 200 onwards, chemotherapy consisted of
Carboplatin (AUC 5) and Paclitaxel 175mg/m2 on day 1
every 3 weeks for 6–9 courses.
In the case of complete clinical and radiological remis-
sion following chemotherapy together with normalized
CA125values,“secondlook”surgerybylaparotomywascon-
sidered. While earlier recommendations suggested the use
of “second look” surgery to document histologic complete
remission, this attitude was only routinely carried out in
the context of clinical trials. In presence of residual tumor,
second-line chemotherapy was initiated, the nature and
duration of which depended on the patient’s age, toxicity,
comorbidity, and response to ﬁrst-line therapy.
Statistical analysis: overall survival and disease-free sur-
vival curves were plotted according to the Kaplan-Meier
method and the log-rank test. A Cox model was used to
analyze the correlation between survival and the signiﬁcant
variables studied. A P value less than .05 was considered to
be signiﬁcant.
3. Results
3.1. Patient Characteristics. The mean age was 58 years
(range: 17–88), 53% of patients were under the age of 60,
71.3% were postmenopausal. The average parity for the
entire population was two, while 20.2% of women were
nulliparous.
3.2. Surgical Procedures. Laparotomy with a xiphoid-to-
pubis incision was the preferred incision, used in 94.7%
of cases. Five patients (1.5%) underwent laparoscopy only,
and laparoscopy followed by laparotomy was performed in
another 13 cases (3.8%). Surgical procedures are shown
in Table 1. Omentectomy, TAH, and BSO were performed
in 82.4%, 62.3%, and 82.1% of cases, respectively. Lym-
phadenectomy was neither systematic nor comprehensive;
pelvic lymphadenectomy was performed in 10% of cases
(unilateral: 3.8% or bilateral: 6.2%) and paraaortic lym-
phadenectomy was performed in 14.3% of cases. Over-
all, 18% of women underwent pelvic and/or paraaortic
lymph node resection. Seventy seven women (22.6%) had a
bowelprocedure:appendicectomy(6.6%),mesentericbiopsy
(9.2%), or bowel resection with immediate anastomosis
(3%). The surgical ﬁndings at the end of the surgery for
the entire population showed residual disease less than
one centimeter in 39.8%, of which 20.3% had a complete
macroscopic resection. Residual disease larger than one
centimeter was present in 60.2% of patients, with diﬀuse
peritoneal carcinomatosis in 26.7% of cases.
The majority of patients had FIGO stage III ovarian
cancer: 77.6% (comprising 22.3% cases of stage IIIc) and
22.3% had FIGO stage IV cancer. The most frequent sites of
metastasiswerepleura:51.3%,liver:10.5%,andbothofthese
organs simultaneously: 6.6%.
Theperioperativemorbidity ratewas2.9%(10/340). The
main complications (grade 3 to 5 perioperative morbidity)International Journal of Surgical Oncology 3
Table 1:Surgicalproceduresperformedduringprimarycytoreduc-
tive surgery.
Surgical procedures Number of
patients Percentage
Hysterectomy:
total 152/340 44.7%
subtotal 61/340 17.9%
Salpingo-oophorectomy
(unilateral or bilateral) 279/340 82%
Omentectomy 276/335 (5MD) 82.4%
Bowel procedures:
Appendicectomy 22/335 6.6%
Bowel or peritoneal
biopsies 31/335 9.2%
Resection 10/335 3%
Other 4/335 1.2%
Lymph node resection
(picking)
Pelvic 34/340 10%
Paraaortic 44/308 (32MD) 14.3%
Pelvic and/or
paraaortic 61/340 18%
MD = missing data.
consisted of one intraoperative pneumothorax and three
postoperative complications. One 78-year-old woman died
at day 18 with bilateral pleural eﬀusion and parenchymal
liver metastasis, and 2 patients required redo surgery:one for
postoperative bleeding and another for peritoneal abscess.
3.3. Histopathologic Results. Histologic examination revealed
81.5%ofserousand/orpapillarytumors,7.6%ofendometri-
oid tumors, 3.5% of undiﬀerentiated tumors, 2.6% of
mucinous tumors, and 1.2% of clear cell tumors. All
tumors initially classiﬁed as “mucinous” were reviewed and
reclassiﬁed. Three tumors actually corresponded to primary
gastrointestinal tumors (two colonic and one pancreatic), 3
to pseudomyxoma peritonei, and 4wereﬁnallyreclassiﬁedas
serous tumors.
Histologic examination of lymph node resection was
negative in 21 out of 34 cases (72.4%) for pelvic nodes and in
26 out of 44 cases (53%) for paraaortic lymph nodes.
3.4. Chemotherapy. Nearly all patients (97.9%) received
platinum-based chemotherapy after primary surgery. Seven
patients opted out of chemotherapy. Median time to initi-
ation of chemotherapy was 27 days. Patients treated before
1999 (65.2%) received a combination of platinum-based
and alkylating agent chemotherapy and patients treated after
2000(34.8%)receivedthePaclitaxel-Carboplatin(orCDDP)
combination.
Second-look surgery was performed in 51.5% of cases,
conﬁrming complete remission (histologically proven) in
37.7%, macroscopic residual disease in 56%, microscopic
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Figure 1: Overall survival and optimal surgery.
residual disease in 5.1% and isolated positive peritoneal
cytology in 1.1%.
Second-line chemotherapy was prescribed in 52.3% of
cases with an average of 4 cycles. Subsequent lines depended
on the patient’s condition and previous response.
3.5. Progression-Free and Overall Survivals. The mean fol-
lowup was 101 months (range: 5 to 203 months). At the
time of analysis, 27.9% of women treated according to this
protocol were still alive, and 72% had died, due to disease
progression in 96.3% of cases.
Median overall survival was 32 months (range: 29–
38) with a ﬁve-year overall survival rate of 31.4%. The 5-
year overall survival rate was 24.2% when residual disease
measured more than one centimeter, 43.5% when surgery
was optimal (Figure 1), and 55.4% in the absence of any
residual disease. The median disease-free survival was 19
months with a ﬁve-year disease-free survival rate of 17.8%.
Univariate analysis of prognostic factors aﬀecting ﬁve-
year overall survival identiﬁed several signiﬁcant factors. As
shown in Table 2, the results of primary surgery, age at
diagnosis,stageofdisease,andresultsofsecond-looksurgery
were signiﬁcant. Five-year progression-free survival was
inﬂuenced by optimal debulking surgery, tumor histology,
and type of chemotherapy.
The Cox model was used to calculate the relative
weight of the prognostic factors found to be signiﬁcant for
overall survival in univariate analysis. As shown in Table 3,
residual disease larger than one centimeter was associated
with a hazard ratio of 2.2 [1.53–3.15] (P = 2 ·10
−1).
Menopausal status also very signiﬁcantly inﬂuenced overall
survival, as the hazard ratio for postmenopausal women
was 1.47 [1.10–1.96] (P = 7 ·10
−3). Analysis of the type4 International Journal of Surgical Oncology
Table 2: Predictive factors of survival.
Predictive factors Number of
patients
Overall survival Disease-free survival
5-year survival
(%) P 5-year survival
(%) P
Age
<60 years 180 36.1 P = .002 27.7 P = .68
≥60 years 160 26.1 26.9
Menopausal status
No 95 43.7 P = .001 31.5 P = .128
Yes 237 36.4 25.4
Residual disease after
surgery
<1cm(without
residual disease) 135 (69) 43.5 (55.4) P = .0002 27.6 (40.6) P = .58
≥1cm 204 24.2 26.7
Lymph node dissection
(picking)
No 279 29 P = .02 24.8 P = .01
Yes 61 42.5 37.8
FIGO stage
III 264 34.6 P = .002 25.7 P = .15
IV 76 19.1 33.6
Histology
Serous 277 31.2 26.3
Mucinous 9 22.2 P = .005 48.6 P = .0007
Endometrioid 26 45.0 42.9
Clear cell 4 25.0 25.0
Undiﬀerentiated 12 38.9 —
Other 12 8.3 —
Grade (2 classes)
1 13 58.6 P = .005 60.0 P = .05
2 and 3 140 24.8 16.0
Chemotherapy
Platinum and
alkylating agents 217 30.3 P = .107 38.2 P = .02
Platinum and
Paclitaxel 116 34.6 26.7
NS = not signiﬁcant.
of chemotherapy showed better results for the Platinum-
Paclitaxel combination compared to the platinum-alkylating
agent combination, with a hazard ratio of 0.72 [0.53–0.97]
(P = 3 ·10
−2).
4. Discussion
Maximal cytoreduction was by far the most important
prognostic parameter in the meta-analysis by Bristow et al.
[3] which included 81 published trials and 6,885 advanced
ovarian cancer patients. Depending on whether or not
complete primary debulking could be achieved, the median
disease-free survival was 22 months versus 14 months and
themedianoverallsurvivalwas52monthsversus26months,
respectively.Byclassifyingpatientsincohortsasafunctionof
the degree of cytoreduction that could be performed, a 10%
increaseinthepopulationabletoreceivemaximalcytoreduc-
tion was associated with a 5.5% increase in median survival
time. This meta-analysis therefore powerfully suggested that
the primary objective of gynecologic oncology surgeons
should be to attempt the most radical approach to eliminate
all residual disease by the end of the primary operation. Is
suchamaximallyaggressivesurgicalapproachinthepatient’s
long-term best interests? Advanced ovarian cancer patients
are already frail due to their heavy tumor load, age, potential
comorbidity (ASA predictive score), and nutritional status
(low-preoperative albumin levels), and all of these param-
eters must be taken into account in the surgical decision.International Journal of Surgical Oncology 5
Table 3: Multivariate analysis of overall survival (Cox model).
N = 324 Hazard ratio P
Optimal surgery
Yes 1 P = 7 ·10
−3
No 2.2 [1.53–3.15]
Menopausal status
No 1 P = 2 ·10
−4
Yes 1.47 [1.10–1.96]
Chemotherapy
Platinum/alkylating agents 1 P = 3 ·10
−2
Platinum/taxanes 0.72 [0.53–0.97]
To achieve maximal cytoreduction in advanced ovarian
cancer, some authors perform multiple visceral resections,
resection of diaphragmatic tumor seedings, hepatic, gastric,
duodeno-pancreatic procedures, vascular, or even urinary
tract resections in addition to the standard TAH BSO and
omentectomy. Although the perioperative mortality of this
type of surgery is low [4], the severe morbidity rate is high,
ranging from 20 to 35% according to the literature [4], while
the survival gain is unclear.
The types of surgical procedures performed at Institut
Curie were consistent over the years and with successive
teams. Radical procedures, as described by Obermair et al.
[8] and Bristow et al. [9], and particularly highly radical
surgery as described by Chen et al. [10], Yildirim and
Sanci [11], and Silver [12] were generally considered not
to be in the patient’s best interests. Particular emphasis is
placed in our center on avoidance of adverse eﬀects, such as
short small bowel syndrome or permanent stoma, and the
need for major vascular surgery. However, bowel resection
was considered acceptable when it could be performed in
a single procedure allowing either complete tumor resec-
tion or prevention of a potential risk of imminent bowel
obstruction.Aboveall,itwasconsideredthatbowelresection
must not delay initiation of chemotherapy. In the present
series, the type and extent of surgical procedures beyond
a“ c o m p r e h e n s i v ee ﬀort at optimal cytoreductive surgery”
involved bowel resections in only 3% of patients, extensive
biopsies on bowel or peritoneum in 9.2%, and lymph node
resection in 18%. Despite these small numbers of “aggressive
procedures”, our results compare favourably with those of
other studies [13–16], in which the authors performed more
radical surgery with the corollary of higher intraoperative
and postoperative complications (Table 4) and remain in
full agreement with the data published by other centers (as
reviewed by Bristow et al.). The median 5-year survival rates
observed in the very restrictive group of patients who could
be totally debulked (no residual disease) at the end of the
primary operation was 55.3%, which compares favorably
to the results reported by Silver [12] and Eisenkop et al.
[13]. Of interest are the slightly better long-term results in
our group of patients with postoperative residual disease
>1cm, suggesting that the better outcome of our patient
population could have been potentially inﬂuenced by more
rapid initiation of chemotherapy. Postoperative gastroin-
testinal ﬁstulas or major fatigue as well as slow recovery
of bowel function may delay initiation of chemotherapy,
particularly when chemotherapy is associated with the newer
antiangiogenic agents. We believe that the management
of advanced ovarian cancer patients must be based on a
concerted eﬀort between surgeons, clinical oncologists, and
a supportive care team. A recent retrospective study [17]
has nevertheless shown that patients requiring very invasive
procedures to achieve maximal cytoreduction at primary
surgery have improved responses to ﬁrst-line chemotherapy,
and comparable outcome to those operated by so-called
“standard” techniques. This study was not randomized and
remains inconclusive.
The diagnostic staging role of lymph node dissection has
been clearly established and has been taken into account in
the FIGO classiﬁcation since 1987. The frequency of lymph
node invasion increases with clinical stage and ranges from
55% to 74% in stage III and 65% to 75% in stage IV patients
[18–21]. While valuable for staging of early ovarian cancer,
the beneﬁt of systematic lymph node dissection remains
controversial in advanced disease, in terms of curative intent.
It was not performed on a regular basis as part of the
primary cytoreductive surgery in our population, as we
considered that the therapeutic beneﬁt of this procedure in
t e r m so fs u r v i v a lh a sn o tb e e nd e m o n s t r a t e di np r o s p e c t i v e
trials. The recent EORTC trial [22] evaluating the impact
of chemotherapy in early stage ovarian cancer emphasized
the better results obtained in precisely staged patients, but
understaging of the disease in advanced stages does not
modify the indication for chemotherapy. Some authors con-
sider lymph node metastases to be sites of chemoresistance;
according to Wu et al. [23], lymph nodes are metastatic in
77% of cases on second-look surgery after complete primary
treatment. A therapeutic beneﬁt of lymph node dissection
has been claimed by several authors based on retrospective
studies. Burghardt et al. [24] reported a 5-year survival of
13% in the absence of lymph node resection compared to
53% when lymph node dissection was performed in stage III
patients. In stage II, III, and IV patients, Di Re et al. [25],
similarly reported a 5-year survival of 30% in the absence
of lymph node resection compared to 46% following lymph
node resection. However, the only randomized prospective
study, by Panici et al. [26] failed to demonstrate a signiﬁcant
beneﬁt in terms of overall survival, while also showing
the need for more frequent transfusions and a signiﬁcantly
longer operating time. This milestone study, which however
onlyaccruedslowlyover12years,randomizedstageIIIb,IIIc,
and stage IV patients (n = 427) to arms with or without
systematic pelvic and paraaortic lymph node dissection.
During surgery, in the case of palpable nodes in patients not
randomized to systematic resection, lymph node “picking”
was allowed. This study demonstrated a positive impact
on disease-free survival (29.4 months versus 22.4 months)
in favor of systematic lymph node dissection, but showed
absolutely no eﬀect on overall survival, with median survival
times of 58.7 months and 56.3 months, respectively. In our
retrospectiveevaluation,only61patients(17.9%)underwent
lymph node resection of palpable nodes (>1cm in diameter)6 International Journal of Surgical Oncology
Table 4: Comparison with other studies.
Author, year n %s t a g eI V
Optimal surgery 5-year survival
Residual
disease % Residual
disease %
Eisenkop et al., 1998
[13] 163 17% 0cm 98.8% 0 52%
>0 29%
Scarabelli et al., 2000
[14] 66 11% <2cm 100% 0 42.2%
>0-1 21.3%
Chi et al., 2001 [15] 282 23% <1cm 26% 0-1 50%
>1-2 28%
>2 21%
Eisenkop, et al., 2003
[16] 408 0% <1cm 96% 0-1 52%
>1-2 30%
>20 %
Present study 340 22.75% <1cm 40% 0 55.4%
>0-1 43.5%
>1 24.2%
or complete lymph node resection. Consequently, our group
of patients with lymph node resections was heterogeneous
andthenumbersweretoosmalltodemonstrateastatistically
signiﬁcant diﬀerence. It should also be noted that, in the
absence of complete lymph node dissection, patients with
early stage ovarian cancer may have been understaged and
that inclusion of these stage IIIc patients (due to node
positive disease) with a better prognosis [27] than patients
with peritoneal deposits, may have inﬂuenced survival data.
Patient outcome at Institut Curie was evaluated over a
very long period, introducing a large number of variables
over time. In this retrospective study, administration of
platinum agents remained constant over the years, consisting
of CDDP prior to 2000 and Carboplatin after 2000. The ﬁrst-
line chemotherapy protocols were fairly consistently admin-
isteredtoallpatientswithonly7exceptions.Twothirdsofthe
total patient population was treated by the Ovaire A-Ovaire
B protocol. One third of the total population, subsequent
to 2000, received a Carboplatin-Taxane regimen as ﬁrst-line
chemotherapy. It is noteworthy that in subsequent lines of
treatment the choices of drugs varied substantially, depend-
ing on various factors, including the patient’s response,
toxicity, performance index and comorbidity. Interestingly,
the change from pre- to post 2000 protocols did not appear
to result in an enhanced progression-free survival. In fact,
PFS was signiﬁcantly shorter (P<. 005) in the Carboplatin-
Taxol group (median PFS of 26.7 versus 38.2 months) than
in the group treated before 2000, but the more recent patient
population had a small sample size with limited followup.
The standard chemotherapy prior to 200 was continued for
a period of 6 months, possibly delaying the onset of relapse.
Seemingly in contradiction, overall survival appeared to be
slightly better in the Carboplatin-Taxol group (median OS
of 34.6 versus 30.3 months, (P<. 05)), but again more
recently treated patients had probably received many more
subsequent lines of treatment, using newer drugs, and may
have beneﬁted from repeated surgical treatments and better
supportive care. These data are consistent with several those
published trials [28, 29].
While very few changes were made to ﬁrst-line systemic
therapies up until 2005 and virtually all patients received one
of the two major platinum-based chemotherapy protocols,
considerable progress has been made in terms of subsequent
lines of treatment and other aspects of patient management
such as surgical and anesthetic techniques and supportive
care. More recently, speciﬁc molecular subgroups with a
better response to chemotherapy, particularly to alkylating
agents, have been identiﬁed, as well documented in a case-
control study by the Royal Marsden hospital, describing
the clinical features and outcome of patients with epithelial
ovarian cancer associated with BRCA1 and BRCA2 muta-
tions [30]. In a multivariate Cox analysis, the following 4
variables: BRCA status, stage (4 versus 2/3), age at diagnosis
as well as year of diagnosis were signiﬁcant parameters for
outcome. Patients with the “BRCAness syndrome” appear
to be associated with higher response rates, duration of
response, and capability to respond to several lines of
chemotherapy and merit a more systematic evaluation in the
future. Prior to 2000, results on genetic testing were available
in only a minority of patients in our center, and a family
historyofbreastorovariancancerwasalsonotsystematically
registered for all patients.
Outcome as a function of tumor histology is another
variable that must be taken into account in the future,
especially as diﬀerent histologic subtypes may respond to
diﬀerent types of chemotherapy. A systematic pathologic
review of all mucinous tumors reclassiﬁed 16 of the initial
25 mucinous ovarian tumors into primary gastrointestinalInternational Journal of Surgical Oncology 7
tumors. Mucinous type histology may also be associated
with almost twice the hazard ratio of death as compared
to endometrioid type histology according to a recent report
by Winter et al. [31]. Similar data have been published by
other authors and molecular typing may be helpful to avoid
erroneous classiﬁcations, particularly as these tumors may
not be very sensitive to taxane and carboplatin regimens
[32, 33].
In conclusion, complete surgical resection of advanced
ovarian cancer is likely dependent on initial tumor volume,
as complete resection is obtained more easily for less bulky
tumors. However, tumor bulk is not the only parameter and
biological variables may also play a role. Genomic proﬁle
analysis has been proposed as a promising tool for the
future. Berchuck et al. [34] determined a genomic proﬁle
predictive of complete tumor resection, suggesting that com-
pleteness of resection may depend on the inherent biological
aggressiveness (or indolence) of the tumor. Tumor stromal
and proangiogenic properties as well as its immunological
characteristics and inﬂammatory cytokine proﬁles may all
inﬂuencetumoradhesiveandinvasivepropertiesandthereby
inﬂuence the ease of tumor resection.
In the near future, primary cytoreductive surgery re-
mains the primary option of treatment for advanced ovarian
cancer patients, but we feel that highly mutilating surgery
may be foregone by an upfront systemic therapy which
should ideally be tailored to the tumor molecular character-
istics. The number of courses of systemic therapy remains
another subject of debate, but possibly the most beneﬁcial
approachforthepatientwouldbeanindividualizedduration
of treatment until best response as evaluated by serum
markers.
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